Pharmacologic Modulation of Hippocampal Activity in Psychosis
Overview
- Phase
- Phase 2
- Intervention
- Levetiracetam 500 mg
- Conditions
- Schizophrenia; Psychosis
- Sponsor
- Vanderbilt University Medical Center
- Enrollment
- 1
- Locations
- 1
- Primary Endpoint
- Hippocampal Activity (Arterial Spin Labeling [ASL] Study)
- Status
- Terminated
- Last Updated
- 4 years ago
Overview
Brief Summary
The purpose of this study is to test whether administration of levetiracetam (LEV), a commonly used anti-epileptic that alters neurotransmitter release, can reduce hippocampal hyperactivity. Specifically, we will utilize two functional magnetic resonance imaging (MRI) techniques: 1) blood oxygen level dependence (BOLD) contrast will assess activity with a visual scene processing task that engages the anterior hippocampus and 2) arterial spin labeling (ASL) will assess baseline activity. This study will also assess whether patients have improvement in their symptoms after receiving LEV. Previous studies in people with psychotic disorders have shown that the hippocampus is hyperactive and more activity correlates with worsening of clinical symptoms. Therefore, the aim of this study is to use an intervention to further understand the underlying mechanisms of the hippocampus in psychosis.
Investigators
Stephan Heckers
Department Chair
Vanderbilt University Medical Center
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Arms & Interventions
Levetiracetam (LEV) 500 mg
Participants will take their first dose of 500 mg LEV. After a two hour time window, the participants will complete MRI study. After MRI, patients will begin a 2-week intervention with 250 mg BID oral LEV.
Intervention: Levetiracetam 500 mg
Outcomes
Primary Outcomes
Hippocampal Activity (Arterial Spin Labeling [ASL] Study)
Time Frame: 2 hours and 2 weeks after administration
Change in ASL signal after drug administration
Hippocampal Recruitment (BOLD Study)
Time Frame: 2 hours and 2 weeks after administration
Change in BOLD signal after drug administration
Secondary Outcomes
- Positive and Negative Symptoms(2 weeks after administration)
- Cognitive Symptoms(2 weeks after administration)